Stereotactic Percutaneous Electrochemotherapy as a New Minimal Invasive Treatment Modality for Primary and Secondary Liver Malignancies
<b>Background and Objectives</b>: To report on the first results of safety, efficacy, and outcome of CT-navigated stereotactic percutaneous electrochemotherapy (SpECT) in patients with primary and secondary liver malignancies. <b>Methods</b>: This retrospective study included...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/12/12/2870 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846105669324767232 |
|---|---|
| author | Lukas Luerken Andrea Goetz Vinzenz Mayr Liang Zhang Alexandra Schlitt Michael Haimerl Christian Stroszczynski Hans-Jürgen Schlitt Matthias Grube Arne Kandulski Ingo Einspieler |
| author_facet | Lukas Luerken Andrea Goetz Vinzenz Mayr Liang Zhang Alexandra Schlitt Michael Haimerl Christian Stroszczynski Hans-Jürgen Schlitt Matthias Grube Arne Kandulski Ingo Einspieler |
| author_sort | Lukas Luerken |
| collection | DOAJ |
| description | <b>Background and Objectives</b>: To report on the first results of safety, efficacy, and outcome of CT-navigated stereotactic percutaneous electrochemotherapy (SpECT) in patients with primary and secondary liver malignancies. <b>Methods</b>: This retrospective study included 23 consecutive lesions in 22 patients who underwent SpECT for primary and secondary malignant liver lesions with locally curative intention. The endpoints were primary technique efficacy (PTE), local tumor progression (LTP), time to progression (TTP), and occurrence of adverse events. <b>Results</b>: The mean maximum diameter of the treated lesions was 42 mm (range: 16 mm–72 mm). Eight lesions were hepatocellular carcinoma (34.8%), five lesions were colorectal liver metastases (21.7%), three lesions were cholangiocellular carcinoma (13.0%), and the other seven lesions were liver metastases from different primary cancers (30.4%). PTE was achieved for 22 lesions (95.7%). The mean follow-up time was 15 months (0–39 months). No LTP was observed. In six patients (27.3%), hepatic tumor progression was observed during follow-up with a mean TTP of 3.8 months (2–8 months). In 10 procedures (43.5%), minor complications (1 CIRSE Grade 2) and side effects occurred, but no major complications were observed. <b>Conclusions</b>: SpECT seems to be a safe and effective new local treatment modality for primary and secondary liver malignancies. |
| format | Article |
| id | doaj-art-e3ce934e01c1470592e495fb04d83d19 |
| institution | Kabale University |
| issn | 2227-9059 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj-art-e3ce934e01c1470592e495fb04d83d192024-12-27T14:13:07ZengMDPI AGBiomedicines2227-90592024-12-011212287010.3390/biomedicines12122870Stereotactic Percutaneous Electrochemotherapy as a New Minimal Invasive Treatment Modality for Primary and Secondary Liver MalignanciesLukas Luerken0Andrea Goetz1Vinzenz Mayr2Liang Zhang3Alexandra Schlitt4Michael Haimerl5Christian Stroszczynski6Hans-Jürgen Schlitt7Matthias Grube8Arne Kandulski9Ingo Einspieler10Department of Radiology, University Hospital Regensburg, 93053 Regensburg, GermanyDepartment of Radiology, University Hospital Regensburg, 93053 Regensburg, GermanyDepartment of Radiology, University Hospital Regensburg, 93053 Regensburg, GermanyDepartment of Radiology, University Hospital Regensburg, 93053 Regensburg, GermanyDepartment of Radiology, University Hospital Regensburg, 93053 Regensburg, GermanyDepartment of Diagnostic and Interventional Radiology, Klinikum Würzburg Mitte gGmbH, 97070 Würzburg, GermanyDepartment of Radiology, University Hospital Regensburg, 93053 Regensburg, GermanyDepartment of Surgery, University Hospital Regensburg, 93053 Regensburg, GermanyDepartment of Internal Medicine III, Hematology and Oncology, University Hospital Regensburg, 93053 Regensburg, GermanyDepartment of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, GermanyDepartment of Radiology, University Hospital Regensburg, 93053 Regensburg, Germany<b>Background and Objectives</b>: To report on the first results of safety, efficacy, and outcome of CT-navigated stereotactic percutaneous electrochemotherapy (SpECT) in patients with primary and secondary liver malignancies. <b>Methods</b>: This retrospective study included 23 consecutive lesions in 22 patients who underwent SpECT for primary and secondary malignant liver lesions with locally curative intention. The endpoints were primary technique efficacy (PTE), local tumor progression (LTP), time to progression (TTP), and occurrence of adverse events. <b>Results</b>: The mean maximum diameter of the treated lesions was 42 mm (range: 16 mm–72 mm). Eight lesions were hepatocellular carcinoma (34.8%), five lesions were colorectal liver metastases (21.7%), three lesions were cholangiocellular carcinoma (13.0%), and the other seven lesions were liver metastases from different primary cancers (30.4%). PTE was achieved for 22 lesions (95.7%). The mean follow-up time was 15 months (0–39 months). No LTP was observed. In six patients (27.3%), hepatic tumor progression was observed during follow-up with a mean TTP of 3.8 months (2–8 months). In 10 procedures (43.5%), minor complications (1 CIRSE Grade 2) and side effects occurred, but no major complications were observed. <b>Conclusions</b>: SpECT seems to be a safe and effective new local treatment modality for primary and secondary liver malignancies.https://www.mdpi.com/2227-9059/12/12/2870HCCiCCAliver cancerliver metastasisinterventional oncologypercutaneous tumor ablation |
| spellingShingle | Lukas Luerken Andrea Goetz Vinzenz Mayr Liang Zhang Alexandra Schlitt Michael Haimerl Christian Stroszczynski Hans-Jürgen Schlitt Matthias Grube Arne Kandulski Ingo Einspieler Stereotactic Percutaneous Electrochemotherapy as a New Minimal Invasive Treatment Modality for Primary and Secondary Liver Malignancies Biomedicines HCC iCCA liver cancer liver metastasis interventional oncology percutaneous tumor ablation |
| title | Stereotactic Percutaneous Electrochemotherapy as a New Minimal Invasive Treatment Modality for Primary and Secondary Liver Malignancies |
| title_full | Stereotactic Percutaneous Electrochemotherapy as a New Minimal Invasive Treatment Modality for Primary and Secondary Liver Malignancies |
| title_fullStr | Stereotactic Percutaneous Electrochemotherapy as a New Minimal Invasive Treatment Modality for Primary and Secondary Liver Malignancies |
| title_full_unstemmed | Stereotactic Percutaneous Electrochemotherapy as a New Minimal Invasive Treatment Modality for Primary and Secondary Liver Malignancies |
| title_short | Stereotactic Percutaneous Electrochemotherapy as a New Minimal Invasive Treatment Modality for Primary and Secondary Liver Malignancies |
| title_sort | stereotactic percutaneous electrochemotherapy as a new minimal invasive treatment modality for primary and secondary liver malignancies |
| topic | HCC iCCA liver cancer liver metastasis interventional oncology percutaneous tumor ablation |
| url | https://www.mdpi.com/2227-9059/12/12/2870 |
| work_keys_str_mv | AT lukasluerken stereotacticpercutaneouselectrochemotherapyasanewminimalinvasivetreatmentmodalityforprimaryandsecondarylivermalignancies AT andreagoetz stereotacticpercutaneouselectrochemotherapyasanewminimalinvasivetreatmentmodalityforprimaryandsecondarylivermalignancies AT vinzenzmayr stereotacticpercutaneouselectrochemotherapyasanewminimalinvasivetreatmentmodalityforprimaryandsecondarylivermalignancies AT liangzhang stereotacticpercutaneouselectrochemotherapyasanewminimalinvasivetreatmentmodalityforprimaryandsecondarylivermalignancies AT alexandraschlitt stereotacticpercutaneouselectrochemotherapyasanewminimalinvasivetreatmentmodalityforprimaryandsecondarylivermalignancies AT michaelhaimerl stereotacticpercutaneouselectrochemotherapyasanewminimalinvasivetreatmentmodalityforprimaryandsecondarylivermalignancies AT christianstroszczynski stereotacticpercutaneouselectrochemotherapyasanewminimalinvasivetreatmentmodalityforprimaryandsecondarylivermalignancies AT hansjurgenschlitt stereotacticpercutaneouselectrochemotherapyasanewminimalinvasivetreatmentmodalityforprimaryandsecondarylivermalignancies AT matthiasgrube stereotacticpercutaneouselectrochemotherapyasanewminimalinvasivetreatmentmodalityforprimaryandsecondarylivermalignancies AT arnekandulski stereotacticpercutaneouselectrochemotherapyasanewminimalinvasivetreatmentmodalityforprimaryandsecondarylivermalignancies AT ingoeinspieler stereotacticpercutaneouselectrochemotherapyasanewminimalinvasivetreatmentmodalityforprimaryandsecondarylivermalignancies |